Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
216.3 USD | +2.04% | -0.83% | -16.40% |
Mar. 25 | Dyne Therapeutics President, CEO Joshua Brumm Resigns, John Cox Named Successor; Shares Drop 7% Pre-Bell | MT |
Mar. 19 | BIOGEN : Jefferies confirms its Buy rating on the stock | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.40% | 31.45B | |
+0.44% | 90.27B | |
+10.00% | 44.05B | |
+44.36% | 23.35B | |
-8.10% | 16.72B | |
-25.64% | 15.09B | |
-9.03% | 12.82B | |
-9.37% | 11.95B | |
+98.58% | 7.67B | |
+1.42% | 8.71B |
- Stock
- Equities
- Stock Biogen Inc. - Nasdaq
- News Biogen Inc.
- Mizuho Securities Raises Biogen to Buy From Neutral, Price Target to $270 From $207 on Lecanemab Trial Data